Group 1 - Blackstone is the world's largest private equity firm with over $1 trillion in assets under management, increasingly focusing on biopharma investments [3][6] - Recent investments include $400 million for Teva Pharmaceutical's gut disease drug and $700 million for Merck & Co.'s cancer therapy, with Blackstone receiving future royalties [3][4] - Blackstone's BXLS platform has raised the largest life sciences private fund at $6.3 billion, which is nearly 40% larger than its previous fund of $4.6 billion [6][7] Group 2 - The BXLS platform has managed $15 billion in assets and has produced 34 approved innovative medicines and devices, with late-stage assets having an 86% approval rate, outperforming the industry average [6][7] - Blackstone's partnerships have included significant deals with companies like Johnson & Johnson and Novartis, indicating a strong presence in the biopharma sector [5][6]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 30, 2026 [3]. Core Insights - The innovative drug sector is experiencing a significant configuration opportunity, with major domestic pharmaceutical companies reporting rapid growth in innovative drugs. The development model has shifted from solely relying on financing to a comprehensive approach that includes product commercialization, overseas R&D licensing, and financing [4]. - The Chinese innovative drug market has seen a surge in business development (BD) events, with 49 BD events recorded in 2026, totaling over $33 billion in upfront payments and nearly $570 billion in total deal value. The first quarter of 2026 alone surpassed the total transaction volume of 2024 [4]. - The innovative drug index outperformed the CSI 300 index by 4.44 percentage points during the week of March 21-27, 2026, with a growth rate of 3.03% [4]. Summary by Sections 1. Innovative Drug Highlights - Major domestic pharmaceutical companies like Heng Rui Medicine and China Biopharmaceuticals have reported rapid growth in innovative drugs, with biotech firms like BeiGene and Innovent Biologics turning significant losses into profits [4]. - The trend of Chinese innovative drugs going global is strong, with a notable increase in BD events and a focus on clinical data quality and long-term market value [4]. 2. Tumor Immunotherapy 2.0 Era - China continues to lead in the development of PD-1/VEGF bispecific antibodies, with significant partnerships and clinical advancements. The market potential for PD-1 bispecifics is expected to surpass that of PD-1 monotherapy [5]. - The collaboration between domestic companies and multinational corporations (MNCs) is intensifying, with a focus on clinical data and market rights sharing [5]. 3. New Technologies and Molecules - The ADC (Antibody-Drug Conjugate) sector is witnessing innovation, with new technologies being integrated to overcome limitations of existing ADCs. The introduction of various therapeutic modalities is expected to expand the applicability of ADCs [6]. 4. Small RNA Collaborations - The small RNA sector is seeing increased mergers and collaborations, with significant deals being made to develop innovative therapies for metabolic disorders. The market for small RNA drugs is rapidly industrializing, with notable sales growth for products like Leqvio [7]. 5. Price Control and Raw Materials - The report highlights the price elasticity of certain raw materials, particularly vitamins, which have seen significant price increases due to geopolitical factors and supply chain dynamics. Vitamin E and A prices have risen by 81.98% and 76% respectively since the beginning of the year [9]. 6. CDMO and CXO Trends - The report emphasizes the importance of CDMO (Contract Development and Manufacturing Organization) in driving orders for large products, with recommendations for companies like Yino Science and Pruis [12]. 7. Recommended Companies and Stock Picks - The report suggests focusing on companies leading in innovative drugs, ADC technology, small RNA therapies, and those with pricing power in raw materials. Specific recommendations include Rongchang Biopharmaceuticals, Sunway Biopharma, and others [12][13].

Core Insights - Alnylam Pharmaceuticals (ALNY) reported $2.99 billion in net product revenues for 2025, marking an 81% year-over-year increase, driven by four approved drugs [1][10] - The company is investing in a robust pipeline, with key candidates including cemdisiran, mivelsiran, and zilebesiran, aimed at sustaining long-term growth [2][6] - Alnylam's Amvuttra, its leading drug, generated $2.31 billion in global sales in 2025, reflecting a 138% year-over-year growth [8][10] Financial Performance - The total net product revenues of $2.99 billion in 2025 represent a significant increase of 81% compared to the previous year [1][10] - Amvuttra's sales of $2.31 billion in 2025 highlight its strong market demand and performance [8][10] Pipeline Development - Alnylam is advancing several key programs, including cemdisiran, which has shown promising results in phase III studies for generalized myasthenia gravis [3][10] - Zilebesiran is undergoing a global phase III study to evaluate its effectiveness in reducing major adverse cardiovascular events [5][10] - Mivelsiran is being developed for early-onset Alzheimer's disease and cerebral amyloid angiopathy, with a phase II study expected to start in 2026 [6][10] Market Competition - Amvuttra faces competition from Pfizer's Vyndaqel/Vyndamax and BridgeBio's Attruby, which are already approved for similar indications [9][10] - Despite its differentiated clinical profile, Amvuttra's competitors offer advantages such as oral administration and lower list prices [9] Stock Performance and Valuation - Alnylam's stock has decreased by 31.4% over the past six months, underperforming the industry and the S&P 500 index [13] - The company's shares currently trade at a price/sales ratio of 11.55, significantly higher than the industry average of 2.39, although below its five-year mean of 19.37 [16]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 1, 2026 [1] Core Insights - The supply-side variables in the pharmaceutical industry are increasing, leading to an expansion in price adjustments. The raw material drug industry is particularly sensitive to these changes, with the penicillin supply chain already experiencing price rebounds. For instance, the import price limit for 6-APA has been set at approximately 260 RMB/kg, prompting domestic companies to raise their prices [2] - The GLP-1 oral medication era is actively beginning, with Chinese companies continuing to explore international markets. Notably, Eli Lilly's sales of its GLP-1 drug reached 36.5 billion USD in 2025, and the oral version of semaglutide has been launched in the U.S. market, showing strong initial prescription numbers [3] - The small nucleic acid field is witnessing ongoing collaborations and authorizations, with significant mergers and acquisitions occurring in 2026. For example, China National Pharmaceutical Group is acquiring a domestic siRNA innovator for 1.2 billion RMB [4] - The retail pharmaceutical market showed positive trends in Q4 2025, with a retail scale of 58.8 billion RMB, although the annual growth rate remained slightly negative at -0.57% [5] - The report emphasizes the market value of oral autoimmune drugs, highlighting Takeda's new oral TYK2 inhibitor showing promising results in clinical trials for psoriasis [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 0.58 percentage points in the last week, ranking 25th among 31 sectors [19] - Over the past month, the pharmaceutical industry index fell by 2.67%, also underperforming the CSI 300 index by 2.77 percentage points, ranking 28th [22] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 37.20, which is below the five-year historical average of 30.78 [40] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral medications, indicating a positive outlook for psoriasis treatment [42] 4. Important Industry Policies and News - Recent policies include the approval of 292 medical device products by the National Medical Products Administration, indicating regulatory support for the industry [44] - Significant news includes Eli Lilly's positive clinical trial results for its drug, which may enhance its market position [46]

Core Viewpoint - Novartis demonstrates strong revenue growth driven by innovative drugs, despite facing short-term challenges from market policies and patent expirations [1][3]. Financial Performance - In 2025, Novartis achieved a total revenue of $54.811 billion, reflecting a year-on-year growth of 8.99% [1]. - Key growth drivers include innovative drugs such as Kisqali (44% growth at constant exchange rates), Pluvicto (70% growth), and Scemblix (87% growth) [1]. - The fourth quarter saw significant contributions from these products, offsetting declines in sales from mature products like Entresto, which experienced a 45% year-on-year drop in sales [1]. Product Development Progress - Novartis is advancing its innovation through a "4+5" strategy, focusing on four therapeutic areas and five technology platforms [2]. - In 2025, the company received approval for 13 new products and indications in China, achieving 100% synchronization with global new drug development [2]. - Recent key developments include the approval of Pluvicto for prostate cancer in China, with a production base in Zhejiang expected to be operational by the end of 2026 [2]. - Positive data from late-stage pipelines, including gene therapy OAV101IT and small RNA drug Leqvio, are anticipated, with over 15 key data readouts expected in the next two years [2]. Industry Policy and Environment - Despite the potential of its innovative pipeline, the company faces short-term challenges, including an 11% year-on-year decline in sales in the U.S. market due to the Inflation Reduction Act [3]. - The expiration of the patent for core product Entresto is expected to intensify competition from generics, putting pressure on sales in 2026 [3]. - The current price-to-earnings ratio (TTM) stands at 22.54, indicating a reasonable valuation, but there are concerns regarding the potential impact of policy implementation on profits [3]. Capital Movements - In 2025, the company enhanced shareholder returns through stock buybacks totaling $8.9 billion and a 5.7% year-on-year increase in dividends [4]. - Free cash flow reached $17.686 billion, providing support for research and development as well as acquisitions [4]. - Overall, Novartis's innovative pipeline in oncology and cardiovascular fields shows technological leadership and resilient growth, although short-term patent expirations and policy uncertainties may limit the stock's ability to break historical highs [4].

Key Insights - The report highlights significant capital expenditure increases among the four major CSP manufacturers, driven by demand that is pushing up power semiconductor prices, indicating a robust recovery in the electronic sector [6][7] - The semiconductor industry is expected to reach a historic high in sales in 2025, with a projected increase in demand for computing power due to AI infrastructure investments [8] - The excavator market saw a substantial increase in both domestic and export sales in January 2026, indicating strong demand recovery in the machinery sector [13][14] - The small nucleic acid sector is gaining traction, with notable collaborations and sales growth, reflecting the increasing value of this market segment in the pharmaceutical industry [18][19] Group 1: Electronic Industry - The electronic sector is experiencing a recovery, with AI infrastructure investments leading to a surge in capital expenditures among major CSPs, expected to reach $670 billion in 2026, a 60% increase year-on-year [7] - The global semiconductor sales reached $791.7 billion in 2025, with a projected increase to over $1 trillion in 2026, driven by demand from AI and IoT technologies [8] - The price increase trend in semiconductors is spreading from memory chips to power, analog, and MCU chips, indicating a comprehensive price cycle in the semiconductor industry [8] Group 2: Machinery Industry - In January 2026, excavator sales increased by 49.5% year-on-year, with domestic sales up 61.4% and exports up 40.5%, reflecting strong demand recovery [13][14] - The loader market also saw significant growth, with sales increasing by 48.5% year-on-year, driven by major domestic projects and a growing overseas market [15] - The overall machinery industry is expected to continue its recovery, supported by government policies and infrastructure projects [14][15] Group 3: Pharmaceutical Industry - The small nucleic acid sector is highlighted for its potential, with a recent collaboration between Saint Gene and Gene Tech valued at up to $1.7 billion, showcasing the sector's growth and international recognition [19][20] - The pharmaceutical sector overall saw a slight increase of 0.14% in the last week, with certain sub-sectors like traditional Chinese medicine and medical services performing particularly well [18] - Investment opportunities are identified in biotech firms with core delivery technologies and those focusing on chronic disease areas, indicating a shift towards more sustainable growth in the pharmaceutical market [20]

Financial Data and Key Metrics Changes - Novartis achieved 8% sales growth and 14% core operating income growth for the full year 2025, with a core margin of 40.1%, reached two years ahead of plan [5][34][36] - For Q4, sales declined by 1%, while core operating income increased by 1%, with underlying growth of 3% when excluding one-time adjustments [6][38] - Core EPS rose 17% to $8.98, and free cash flow reached an all-time high of CHF 17.6 billion, growing 8% [34][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% to CHF 4.8 billion for the year, with Q4 growth at 44% [7][8] - Kesimpta grew 36% to $4.4 billion, with a 27% growth in Q4 [10][11] - Pluvicto reached $2 billion in sales, showing 42% constant currency growth [12] - Leqvio achieved blockbuster status with 57% growth for the year [14] - Scemblix also reached blockbuster status with 87% growth in Q4 [15] Market Data and Key Metrics Changes - Novartis reported strong growth in key markets, with Kisqali leading in early breast cancer settings in Germany with over 80% NBRX share [8] - Kesimpta is leading in 9 out of 10 major markets outside the U.S. [11] - Pluvicto has secured approvals in Japan and China, contributing to strong growth outside the U.S. [12] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement power [7] - The company is committed to maintaining a strong pipeline with seven pivotal readouts expected in 2026 [31][49] - Novartis plans to continue investing in R&D, with over $10 billion allocated in 2025 [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a 5%-6% sales CAGR from 2025 to 2030, despite anticipated generic impacts [42][48] - The company expects to return to a core margin of over 40% by 2029 [43] - Management highlighted the importance of pipeline assets in driving future growth [49] Other Important Information - The company completed a CHF 15 billion share buyback program and proposed a dividend increase of 6% [40][27] - The transition of CFO from Harry Kirsch to Mukul Mehta was noted, with Kirsch acknowledging the company's transformation during his tenure [41] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management confirmed that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [54][56] Question: Commercial opportunities for remibrutinib in MS - Management indicated that while B-cell monoclonal antibodies will remain dominant, there is a significant market for oral options, especially for patients preferring non-injectable therapies [61] Question: Risks associated with Pelacarsen's event-based study - Management expressed confidence in the study's design and powering assumptions, despite lower than expected event rates [63]

Financial Data and Key Metrics Changes - Novartis achieved high single-digit sales growth of 8% for the full year 2025, with core operating income increasing by 14% to CHF 21.9 billion, achieving a core margin of 40.1% two years ahead of plan [5][34][36] - In Q4, sales declined by 1% due to gross-to-net impacts and the loss of exclusivity for Entresto, while core operating income increased by 1% [6][34] - Core EPS rose by 17% to $8.98, with free cash flow reaching an all-time high of CHF 17.6 billion, an 8% increase [37][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% year-over-year to CHF 4.8 billion, with Q4 growth at 44% [7][8] - Kesimpta achieved 36% growth to $4.4 billion, with a 27% increase in Q4 [10][11] - Pluvicto reached $2 billion in sales, showing 42% constant currency growth, primarily driven by a 75% increase in the US [12][13] - Leqvio reached blockbuster status with 57% growth for the year and 46% in Q4 [14] - Scemblix also achieved blockbuster status with 87% growth in Q4 [15][16] Market Data and Key Metrics Changes - Novartis reported strong performance in key markets, with Kisqali leading in early breast cancer settings in Germany with over 80% NBRX share [8] - Kesimpta is leading in 9 out of 10 major markets outside the US [11] - Pluvicto has secured approvals in Japan and China, with expectations for strong growth in these markets [12] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement power [7] - The company is committed to maintaining a strong pipeline with 7 pivotal readouts expected in 2026, which could strengthen midterm growth outlook [31][49] - Novartis plans to continue investing in R&D, with over $10 billion allocated in 2025, and is focused on shareholder returns through dividends and share buybacks [39][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a 5%-6% sales CAGR from 2025 to 2030, despite anticipated generic impacts [42][48] - The company expects to return to a core margin of over 40% by 2029 [43] - Management highlighted the importance of pipeline assets and their potential to drive higher growth [49] Other Important Information - The company is transitioning leadership with Mukul Mehta set to take over as CFO in mid-March [5][41] - Novartis is focused on global health initiatives, including the development of new malaria treatments [30] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management noted that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [54][56] Question: Commercial opportunities for remibrutinib in MS - Management acknowledged that while B-cell monoclonal antibodies will remain dominant, there is a significant market for oral options, especially for patients preferring non-injectable therapies [61] Question: Risks associated with Pelacarsen's study - Management expressed confidence in the study's design and powering assumptions, indicating that lower event rates may not pose significant risks [63]

Financial Data and Key Metrics Changes - Novartis achieved high single-digit growth with an 8% increase in sales and a 14% rise in core operating income for the full year 2025, reaching a core margin of 40.1% [4][35] - For Q4, sales declined by 1%, while core operating income increased by 1%, with core EPS rising 2% to $2.03 [5][38] - Free cash flow reached an all-time high of CHF 17.6 billion, growing 8% year-over-year [35][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% year-over-year to CHF 4.8 billion, with Q4 growth at 44% [6][7] - Kesimpta saw a 36% increase to $4.4 billion, with a 27% growth in Q4 [10] - Pluvicto achieved $2 billion in global sales, with a 75% increase in the U.S. [12] - Leqvio reached blockbuster status with 57% growth for the year [14] - Scemblix also reached blockbuster status with 87% growth in Q4 [15] Market Data and Key Metrics Changes - Kisqali's U.S. sales growth was 62%, with over 80% NBRX share in Germany for early breast cancer [7][9] - Kesimpta is leading in NBRX share in 9 out of 10 major markets outside the U.S. [10] - Pluvicto secured approvals in Japan and China, contributing to strong growth outside the U.S. [12] - Scemblix has a 41% NBRX share in the U.S. and 72% in the third-line setting across major markets [17] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement [6] - The company plans to continue investing in R&D while managing productivity improvements [43][44] - Novartis is committed to maintaining a 5%-6% sales CAGR from 2025 to 2030 [44][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit sales growth in 2026 despite anticipated challenges from generic entries [43][44] - The company expects to return to a core margin of over 40% by 2029 [44] - Management highlighted the importance of pipeline advancements and upcoming pivotal readouts in 2026 [32][50] Other Important Information - Novartis has completed its CHF 15 billion share buyback program and initiated a new CHF 10 billion program [41] - The proposed dividend for 2025 is CHF 3.70 per share, marking a 6% increase [41][42] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management noted that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [53][54] Question: Commercial opportunities for remibrutinib in MS - Management indicated that the commercial opportunity will depend on data-driven results, with a significant market for oral options in MS [60][61] Question: Thoughts on Pelacarsen's event-based study risks - Management expressed confidence in the study's design and powering assumptions, despite lower than expected event rates [62][63] Question: Launch plans for Rhapsido and Ianalumab in an MFN world - Management acknowledged the importance of adjusting launch strategies for significant assets like Rhapsido and Ianalumab in the ex-U.S. market [73]

Content Click below to navigate through the document Company overview 2025 financial review 2026 guidance Conclusions Appendix References Q4 2025 Results Investor presentation February 4, 2025 Novartis Q4 Results | February 4, 2026 1 Content Click below to navigate through the document Company overview 2025 financial review 2026 guidance Conclusions This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can general ...